204 related articles for article (PubMed ID: 33348988)
1. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Shinn LT; Vo KA; Reeves DJ
Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
Calvo E; Moreno V; Flynn M; Holgado E; Olmedo ME; Lopez Criado MP; Kahatt C; Lopez-Vilariño JA; Siguero M; Fernandez-Teruel C; Cullell-Young M; Soto Matos-Pita A; Forster M
Ann Oncol; 2017 Oct; 28(10):2559-2566. PubMed ID: 28961837
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
[TBL] [Abstract][Full Text] [Related]
4. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
5. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
[TBL] [Abstract][Full Text] [Related]
6. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V; Paz-Ares L; Besse B; Moreno V; Peters S; Sala MA; López-Vilariño JA; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Zaman K; López R; Ponce S; Boni V; Arrondeau J; Delord JP; Martínez M; Wannesson L; Antón A; Valdivia J; Awada A; Kristeleit R; Olmedo ME; Rubio MJ; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D' Arcangelo M; Santoro A; Villalobos VM; Sands J; Trigo J
Lung Cancer; 2020 Dec; 150():90-96. PubMed ID: 33096421
[TBL] [Abstract][Full Text] [Related]
8. Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting.
Badin F
Cancer Treat Res Commun; 2024; 39():100803. PubMed ID: 38490092
[TBL] [Abstract][Full Text] [Related]
9. Lurbinectedin for the treatment of small cell lung cancer.
Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
Metaxas Y; Kahatt C; Alfaro V; Fudio S; Zeaiter A; Plummer R; Sessa C; Von Moos R; Forster M; Stathis A
Invest New Drugs; 2022 Feb; 40(1):91-98. PubMed ID: 34453241
[TBL] [Abstract][Full Text] [Related]
11. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
Patel S; Petty WJ; Sands JM
Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
[TBL] [Abstract][Full Text] [Related]
13. A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.
Cheng Y; Wu C; Wu L; Zhao J; Zhao Y; Chen L; Xin Y; Zhang L; Pan P; Li X; Li J; Dong X; Tang K; Gao E; Yu F
Sci Rep; 2024 Feb; 14(1):3598. PubMed ID: 38351146
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
Rajput PS; Khan SR; Singh P; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):812-820. PubMed ID: 34229593
[TBL] [Abstract][Full Text] [Related]
15. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
Desai A; Smith CJ; Ashara Y; Orme JJ; Zanwar S; Potter A; Hocum C; Moffett JN; Schwecke AJ; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Molina J; Dimou A; Mansfield AS; Parikh K; Leventakos K
Clin Lung Cancer; 2023 Dec; 24(8):689-695.e1. PubMed ID: 37880074
[TBL] [Abstract][Full Text] [Related]
16. Lurbinectedin in small cell lung cancer.
Manzo A; Sforza V; Carillio G; Palumbo G; Montanino A; Sandomenico C; Costanzo R; Esposito G; Laudato F; Mercadante E; La Manna C; Muto P; Totaro G; De Cecio R; Picone C; Piccirillo MC; Pascarella G; Normanno N; Morabito A
Front Oncol; 2022; 12():932105. PubMed ID: 36110944
[TBL] [Abstract][Full Text] [Related]
17. A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas.
Khoury R; Assi T; Ibrahim R; Ibrahim T; Verret B; Henon C; Bahleda R; Le Cesne A
Curr Treat Options Oncol; 2024 Feb; 25(2):176-190. PubMed ID: 38324075
[TBL] [Abstract][Full Text] [Related]
18. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Peters S; Trigo J; Besse B; Moreno V; Navarro A; Eugenia Olmedo M; Paz-Ares L; Grohé C; Antonio Lopez-Vilariño J; Fernández C; Kahatt C; Alfaro V; Nieto A; Zeaiter A; Subbiah V
Lung Cancer; 2024 Feb; 188():107448. PubMed ID: 38198859
[TBL] [Abstract][Full Text] [Related]
19. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
[TBL] [Abstract][Full Text] [Related]
20. Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
Dumoulin DW; Cantini L; Cornelissen R; Vink M; Klaase L; Slooff K; Tebayna N; Mankor JM; Baart SJ; Hendriks R; Dingemans AC; Willemsen M; Aerts JGJV
Eur J Cancer; 2022 Sep; 172():357-366. PubMed ID: 35834843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
